Latest news

• Another R&D flop for Incyte, but Jakafi keeps delivering

  Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

• NHS chief pledges CAR-T support, but asks for pricing restraint

  Kite’s CAR-T Yescarta (axicabtagene ciloleucel) was the first to be submitted for approval in Europe and is being reviewed by the EMA for diffuse large B-cell lymphoma (DLBCL), ... primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular

• NICE backs Roche’s Gazyvaro after initial rejection

  The UK’s National Institute for Health and Care Excellence (NICE) has recommended Roche’s Gazyvaro as a first-line treatment for lymphoma patients, reversing its earlier stance on the drug. ... Last September the cost-effectiveness watchdog turned

• Novartis files CAR-T therapy CTL109 in Europe

  as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

• Roche's Actemra/RoActemra receives new European approval

  Gazyvaro approved for advanced follicular lymphoma. Meanwhile, the European Commission has also licensed Roche’s Gazyvaro (obinutuzumab) for patients with previously untreated advanced follicular lymphoma. ... with follicular lymphoma who did not